Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
ChemoCentryx to host virtual research and development day » 12:25
04/14/21
04/14
12:25
04/14/21
12:25
CCXI

ChemoCentryx

$48.70 /

+1.55 (+3.29%)

Virtual Research and…

Virtual Research and Development day to be held on April 14 at 12:30 pm. Webcast Link

ShowHide Related Items >><<
CCXI ChemoCentryx
$48.70 /

+1.55 (+3.29%)

CCXI ChemoCentryx
$48.70 /

+1.55 (+3.29%)

03/26/21 Piper Sandler
ChemoCentryx given FDA panel meeting on May 6, says Piper Sandler
03/02/21 H.C. Wainwright
ChemoCentryx price target raised to $101 from $83 at H.C. Wainwright
03/01/21 Stifel
ChemoCentryx initiated with a Buy at Stifel
12/22/20 Piper Sandler
Piper names ChemoCentryx a top pick for 2021, boosts target to $80
CCXI ChemoCentryx
$48.70 /

+1.55 (+3.29%)

  • 11
    Jun
CCXI ChemoCentryx
$48.70 /

+1.55 (+3.29%)

Conference/Events
ChemoCentryx to host virtual research and development day » 04:55
04/14/21
04/14
04:55
04/14/21
04:55
CCXI

ChemoCentryx

$47.07 /

+0.78 (+1.69%)

Virtual Research and…

Virtual Research and Development day to be held on April 14 at 12:30 pm. Webcast Link

ShowHide Related Items >><<
CCXI ChemoCentryx
$47.07 /

+0.78 (+1.69%)

CCXI ChemoCentryx
$47.07 /

+0.78 (+1.69%)

03/26/21 Piper Sandler
ChemoCentryx given FDA panel meeting on May 6, says Piper Sandler
03/02/21 H.C. Wainwright
ChemoCentryx price target raised to $101 from $83 at H.C. Wainwright
03/01/21 Stifel
ChemoCentryx initiated with a Buy at Stifel
12/22/20 Piper Sandler
Piper names ChemoCentryx a top pick for 2021, boosts target to $80
CCXI ChemoCentryx
$47.07 /

+0.78 (+1.69%)

  • 11
    Jun
CCXI ChemoCentryx
$47.07 /

+0.78 (+1.69%)

Conference/Events
ChemoCentryx to host virtual research and development day » 14:39
04/12/21
04/12
14:39
04/12/21
14:39
CCXI

ChemoCentryx

$48.15 /

-1.16 (-2.35%)

Virtual Research and…

Virtual Research and Development day to be held on April 14 at 12:30 pm. Webcast Link

ShowHide Related Items >><<
CCXI ChemoCentryx
$48.15 /

-1.16 (-2.35%)

CCXI ChemoCentryx
$48.15 /

-1.16 (-2.35%)

03/26/21 Piper Sandler
ChemoCentryx given FDA panel meeting on May 6, says Piper Sandler
03/02/21 H.C. Wainwright
ChemoCentryx price target raised to $101 from $83 at H.C. Wainwright
03/01/21 Stifel
ChemoCentryx initiated with a Buy at Stifel
12/22/20 Piper Sandler
Piper names ChemoCentryx a top pick for 2021, boosts target to $80
CCXI ChemoCentryx
$48.15 /

-1.16 (-2.35%)

  • 11
    Jun
CCXI ChemoCentryx
$48.15 /

-1.16 (-2.35%)

Hot Stocks
ChemoCentryx announces poster presentation on CCX559 » 08:32
04/09/21
04/09
08:32
04/09/21
08:32
CCXI

ChemoCentryx

$48.96 /

+0.96 (+2.00%)

ChemoCentryx announced…

ChemoCentryx announced that the Company's orally-administered small molecule PD-L1 inhibitor, CCX559, will be featured in a poster presentation at the virtual 2021 Annual Meeting of the American Association for Cancer Research. The poster presentation, which showcases CCX559's ability to induce anti-tumor immunity, will go live on Saturday, April 10 at 8:30 a.m. ET as part of the Novel Antitumor Agents Session. PD-L1/PD-1 interaction is one of the major checkpoints that limit effector T cell function against cancer cells. As a next generation therapy, small molecule inhibitors of PD-L1 may have advantageous properties compared to approved monoclonal antibodies, such as better penetration into solid tumors, reduced immunogenicity, lack of Fc-mediated side effects, convenience of oral administration, and lower cost of goods. The study featured in the AACR poster presentation demonstrated that CCX559 potentially employs distinct mechanisms to inhibit PD-L1 compared to the anti-human PD-L1 antibodies. In murine tumor models, orally administered CCX559 reduced tumor growth similarly to a clinically-approved anti-human PD-L1 antibody. Based on CCX559's unique mechanism of PD-L1 inhibition, strong anti-tumor activity, desirable drug properties, and good safety profile, the Company plans to advance CCX559 into clinical development in the first half of 2021.

ShowHide Related Items >><<
CCXI ChemoCentryx
$48.96 /

+0.96 (+2.00%)

CCXI ChemoCentryx
$48.96 /

+0.96 (+2.00%)

03/26/21 Piper Sandler
ChemoCentryx given FDA panel meeting on May 6, says Piper Sandler
03/02/21 H.C. Wainwright
ChemoCentryx price target raised to $101 from $83 at H.C. Wainwright
03/01/21 Stifel
ChemoCentryx initiated with a Buy at Stifel
12/22/20 Piper Sandler
Piper names ChemoCentryx a top pick for 2021, boosts target to $80
CCXI ChemoCentryx
$48.96 /

+0.96 (+2.00%)

  • 11
    Jun
CCXI ChemoCentryx
$48.96 /

+0.96 (+2.00%)

Conference/Events
Wells Fargo to hold a virtual conference » 04:55
04/08/21
04/08
04:55
04/08/21
04:55
ADAP

Adaptimmune

$4.96 /

-0.3 (-5.70%)

, AGTC

Applied Genetic

$4.45 /

-0.29 (-6.12%)

, BLCM

Bellicum Pharmaceuticals

$3.50 /

-0.12 (-3.31%)

, BEAM

Beam Therapeutics

$74.42 /

-2.26 (-2.95%)

, AVRO

Avrobio

$11.41 /

-0.3 (-2.56%)

, CLLS

Cellectis

$19.28 /

-0.53 (-2.68%)

, CCXI

ChemoCentryx

$48.00 /

-0.79 (-1.62%)

, CALA

Calithera Biosciences

$2.42 /

-0.065 (-2.62%)

, HALO

Halozyme

$42.36 /

-0.175 (-0.41%)

, IMV

IMV Inc.

$2.96 /

-0.235 (-7.36%)

, MORF

Morphic

$60.76 /

-0.6 (-0.98%)

, MRNA

Moderna

$131.52 /

-2 (-1.50%)

, PGEN

Precigen

$6.79 /

-0.24 (-3.41%)

, QURE

uniQure

$34.51 /

-1.41 (-3.93%)

, TCON

Tracon Pharmaceuticals

$8.78 /

-0.18 (-2.01%)

, STRO

Sutro Biopharma

$21.28 /

-1.6 (-6.99%)

, SGMO

Sangamo

$11.24 /

-0.61 (-5.15%)

, RNA

Avidity Biosciences

$23.58 /

-0.97 (-3.95%)

, RGLS

Regulus

$1.44 /

-0.04 (-2.70%)

, ZIOP

Ziopharm

$3.37 /

-0.045 (-1.32%)

Biotech Corporate Access…

Biotech Corporate Access Day Virtual Conference will be held on April 6-8.

ShowHide Related Items >><<
ZIOP Ziopharm
$3.37 /

-0.045 (-1.32%)

TCON Tracon Pharmaceuticals
$8.78 /

-0.18 (-2.01%)

STRO Sutro Biopharma
$21.28 /

-1.6 (-6.99%)

SGMO Sangamo
$11.24 /

-0.61 (-5.15%)

RNA Avidity Biosciences
$23.58 /

-0.97 (-3.95%)

RGLS Regulus
$1.44 /

-0.04 (-2.70%)

QURE uniQure
$34.51 /

-1.41 (-3.93%)

PGEN Precigen
$6.79 /

-0.24 (-3.41%)

MRNA Moderna
$131.52 /

-2 (-1.50%)

MORF Morphic
$60.76 /

-0.6 (-0.98%)

IMV IMV Inc.
$2.96 /

-0.235 (-7.36%)

HALO Halozyme
$42.36 /

-0.175 (-0.41%)

CLLS Cellectis
$19.28 /

-0.53 (-2.68%)

CCXI ChemoCentryx
$48.00 /

-0.79 (-1.62%)

CALA Calithera Biosciences
$2.42 /

-0.065 (-2.62%)

BLCM Bellicum Pharmaceuticals
$3.50 /

-0.12 (-3.31%)

BEAM Beam Therapeutics
$74.42 /

-2.26 (-2.95%)

AVRO Avrobio
$11.41 /

-0.3 (-2.56%)

AGTC Applied Genetic
$4.45 /

-0.29 (-6.12%)

ADAP Adaptimmune
$4.96 /

-0.3 (-5.70%)

ADAP Adaptimmune
$4.96 /

-0.3 (-5.70%)

08/12/20 Piper Sandler
TCR2 Therapeutics initiated with an Overweight at Piper Sandler
06/01/20 Mizuho
Adaptimmune price target raised to $9 from $3 at Mizuho
05/29/20 JonesTrading
JonesTrading upgrades Adaptimmune to Buy after data alleviates 'key concern'
05/29/20 JonesTrading
Adaptimmune upgraded to Buy from Hold at JonesTrading
AGTC Applied Genetic
$4.45 /

-0.29 (-6.12%)

03/01/21 Stifel
Applied Genetic initiated with a Buy at Stifel
02/02/21 H.C. Wainwright
Applied Genetic price target raised to $24 from $18 at H.C. Wainwright
02/01/21 Roth Capital
Applied Genetic price target raised to $35 from $30 at Roth Capital
11/17/20 Roth Capital
Applied Genetic price target raised to $30 from $26 at Roth Capital
BLCM Bellicum Pharmaceuticals
$3.50 /

-0.12 (-3.31%)

10/30/20
Fly Intel: Top five analyst downgrades
10/30/20 Ladenburg
Bellicum Pharmaceuticals downgraded to Neutral from Buy at Ladenburg
10/30/20 Wells Fargo
Bellicum Pharmaceuticals downgraded to Equal Weight from Overweight at Wells Fargo
10/30/20 Wells Fargo
Bellicum downgraded to Equal Weight from Overweight at Wells Fargo
BEAM Beam Therapeutics
$74.42 /

-2.26 (-2.95%)

03/01/21 Barclays
Beam Therapeutics downgraded to Equal Weight from Overweight at Barclays
02/25/21 Wedbush
Beam Therapeutics price target raised to $112 from $42 at Wedbush
02/16/21
Fly Intel: Top five analyst initiations
02/16/21 Wells Fargo
Beam Therapeutics initiated with an Overweight at Wells Fargo
AVRO Avrobio
$11.41 /

-0.3 (-2.56%)

03/10/21 Stifel
Stifel says Bluebird update on AML provides 'some relief' to other LV players
03/09/21 Barclays
Avrobio initiated with an Overweight at Barclays
03/01/21 Stifel
Avrobio initiated with a Hold at Stifel
02/17/21 Mizuho
Avrobio selloff on Bluebird news a buying opportunity, says Mizuho
CLLS Cellectis
$19.28 /

-0.53 (-2.68%)

03/16/21 Baird
Cellectis upgraded to Outperform from Neutral at Baird
10/15/20 Baird
Cellectis downgraded to Neutral at Baird
10/15/20 Baird
Cellectis downgraded to Neutral from Outperform at Baird
08/19/20
Fly Intel: Top five analyst upgrades
CCXI ChemoCentryx
$48.00 /

-0.79 (-1.62%)

03/26/21 Piper Sandler
ChemoCentryx given FDA panel meeting on May 6, says Piper Sandler
03/02/21 H.C. Wainwright
ChemoCentryx price target raised to $101 from $83 at H.C. Wainwright
03/01/21 Stifel
ChemoCentryx initiated with a Buy at Stifel
12/22/20 Piper Sandler
Piper names ChemoCentryx a top pick for 2021, boosts target to $80
CALA Calithera Biosciences
$2.42 /

-0.065 (-2.62%)

01/05/21 SVB Leerink
Calithera Biosciences downgraded to Market Perform at SVB Leerink
01/05/21 SVB Leerink
Calithera Biosciences downgraded to Market Perform from Outperform at SVB Leerink
01/05/21 Citi
Calithera Biosciences price target lowered to $5 from $10 at Citi
01/05/21 H.C. Wainwright
Calithera Biosciences price target lowered to $4 from $9.50 at H.C. Wainwright
HALO Halozyme
$42.36 /

-0.175 (-0.41%)

01/25/21 BMO Capital
Halozyme price target raised to $65 from $56 at BMO Capital
01/21/21 Benchmark
Halozyme price target raised to $59 from $46 at Benchmark
01/14/21 Piper Sandler
Halozyme price target raised to $50 from $42 at Piper Sandler
01/11/21 Benchmark
Phesgo EU approval/Horizon deal fuel Halozyme increased guidance, says Benchmark
IMV IMV Inc.
$2.96 /

-0.235 (-7.36%)

12/29/20 Raymond James
Raymond James says IMV COVID plans look like 'red herring' to justify delay
07/21/20 Industrial Alliance
IMV Inc. initiated with a Buy at Industrial Alliance
07/14/20 Wells Fargo
IMV Inc. price target raised to $11 from $8.50 at Wells Fargo
05/18/20 Wells Fargo
IMV Inc. upgraded to Overweight on COVID-19 vaccine potential at Wells Fargo
MORF Morphic
$60.76 /

-0.6 (-0.98%)

03/03/21 SVB Leerink
Protagonist Therapeutics price target raised to $41 from $30 at SVB Leerink
03/01/21 Wells Fargo
Morphic Holding price target raised to $103 from $40 at Wells Fargo
02/02/21 RBC Capital
Morphic Holding price target raised to $50 from $35 at RBC Capital
10/26/20 RBC Capital
Morphic Holding initiated with an Outperform at RBC Capital
MRNA Moderna
$131.52 /

-2 (-1.50%)

04/07/21 Jefferies
Catalent pact with Moderna removes potential overhang, says Jefferies
03/15/21 Piper Sandler
Piper Sandler bullish on Moderna as first subject vaccinated in '1283 study
03/01/21 Chardan
Moderna price target raised to $182 from $107 at Chardan
02/26/21 Barclays
Moderna price target raised to $178 from $169 at Barclays
PGEN Precigen
$6.79 /

-0.24 (-3.41%)

03/02/21 B. Riley
Precigen price target raised to $14 from $10 at B. Riley Securities
02/25/21 Stifel
Precigen initiated with a Buy at Stifel
02/22/21 Wells Fargo
Precigen initiated with an Overweight at Wells Fargo
02/18/21
Fly Intel: Top five analyst initiations
QURE uniQure
$34.51 /

-1.41 (-3.93%)

04/01/21
Fly Intel: Top five analyst upgrades
04/01/21 Mizuho
uniQure upgraded to Buy on favorable risk/reward at Mizuho
04/01/21 Mizuho
uniQure upgraded to Buy from Neutral at Mizuho
03/29/21 H.C. Wainwright
uniQure probe 'important first step' toward lifting hold, says H.C. Wainwright
TCON Tracon Pharmaceuticals
$8.78 /

-0.18 (-2.01%)

04/01/21 JonesTrading
Tracon Pharmaceuticals initiated with a Buy at JonesTrading
02/10/21
Fly Intel: Top five analyst initiations
02/10/21 Maxim
Tracon Pharmaceuticals initiated with a Buy at Maxim
12/04/20 H.C. Wainwright
Tracon Pharmaceuticals price target raised to $12 from $7 at H.C. Wainwright
STRO Sutro Biopharma
$21.28 /

-1.6 (-6.99%)

01/28/21 Truist
Sutro Biopharma price target raised to $37 from $24 at Truist
12/02/20 Stifel
Sutro Biopharma initiated with a Buy at Stifel
11/06/20 Piper Sandler
Sutro Biopharma price target raised to $22 from $20 at Piper Sandler
09/18/20 Piper Sandler
Piper Sandler lays out next potential takeover targets in oncology
SGMO Sangamo
$11.24 /

-0.61 (-5.15%)

03/03/21 Wells Fargo
Sangamo price target lowered to $29 from $36 at Wells Fargo
01/05/21 Stifel
Sangamo initiated with a Hold at Stifel
12/16/20 H.C. Wainwright
Sangamo assumed with a Buy at H.C. Wainwright
09/08/20 BofA
Sangamo resumed with a Buy at BofA
RNA Avidity Biosciences
$23.58 /

-0.97 (-3.95%)

07/07/20 Cowen
Avidity Biosciences initiated with an Outperform at Cowen
07/07/20 SVB Leerink
Avidity Biosciences initiated with an Outperform at SVB Leerink
07/07/20 Cowen
Avidity Biosciences initiated with an Outperform at Cowen
07/07/20 Wells Fargo
Avidity Biosciences initiated with an Overweight at Wells Fargo
RGLS Regulus
$1.44 /

-0.04 (-2.70%)

05/04/20 H.C. Wainwright
Regulus price target lowered to $1.50 from $2 at H.C. Wainwright
ZIOP Ziopharm
$3.37 /

-0.045 (-1.32%)

03/12/21 Jefferies
Ziopharm downgraded to Hold from Buy at Jefferies
03/01/21
Fly Intel: Top five analyst downgrades
03/01/21 H.C. Wainwright
Ziopharm downgraded to Neutral from Buy at H.C. Wainwright
07/10/20 Lake Street
Ziopharm took 'important step' with start of CAR-T study, says Lake Street
ZIOP Ziopharm
$3.37 /

-0.045 (-1.32%)

TCON Tracon Pharmaceuticals
$8.78 /

-0.18 (-2.01%)

STRO Sutro Biopharma
$21.28 /

-1.6 (-6.99%)

SGMO Sangamo
$11.24 /

-0.61 (-5.15%)

RNA Avidity Biosciences
$23.58 /

-0.97 (-3.95%)

RGLS Regulus
$1.44 /

-0.04 (-2.70%)

QURE uniQure
$34.51 /

-1.41 (-3.93%)

PGEN Precigen
$6.79 /

-0.24 (-3.41%)

MRNA Moderna
$131.52 /

-2 (-1.50%)

MORF Morphic
$60.76 /

-0.6 (-0.98%)

HALO Halozyme
$42.36 /

-0.175 (-0.41%)

CLLS Cellectis
$19.28 /

-0.53 (-2.68%)

CCXI ChemoCentryx
$48.00 /

-0.79 (-1.62%)

CALA Calithera Biosciences
$2.42 /

-0.065 (-2.62%)

BLCM Bellicum Pharmaceuticals
$3.50 /

-0.12 (-3.31%)

BEAM Beam Therapeutics
$74.42 /

-2.26 (-2.95%)

AVRO Avrobio
$11.41 /

-0.3 (-2.56%)

AGTC Applied Genetic
$4.45 /

-0.29 (-6.12%)

ADAP Adaptimmune
$4.96 /

-0.3 (-5.70%)

  • 03
    Mar
  • 28
    Jan
  • 22
    Jan
  • 16
    Dec
  • 09
    Dec
  • 20
    Nov
  • 01
    Oct
  • 11
    Jun
  • 12
    Jun
  • 02
    Jun
  • 19
    May
  • 12
    May
  • 16
    Apr
MRNA Moderna
$131.52 /

-2 (-1.50%)

ZIOP Ziopharm
$3.37 /

-0.045 (-1.32%)

STRO Sutro Biopharma
$21.28 /

-1.6 (-6.99%)

QURE uniQure
$34.51 /

-1.41 (-3.93%)

PGEN Precigen
$6.79 /

-0.24 (-3.41%)

MRNA Moderna
$131.52 /

-2 (-1.50%)

MORF Morphic
$60.76 /

-0.6 (-0.98%)

HALO Halozyme
$42.36 /

-0.175 (-0.41%)

CCXI ChemoCentryx
$48.00 /

-0.79 (-1.62%)

CALA Calithera Biosciences
$2.42 /

-0.065 (-2.62%)

BLCM Bellicum Pharmaceuticals
$3.50 /

-0.12 (-3.31%)

AVRO Avrobio
$11.41 /

-0.3 (-2.56%)

AGTC Applied Genetic
$4.45 /

-0.29 (-6.12%)

TCON Tracon Pharmaceuticals
$8.78 /

-0.18 (-2.01%)

STRO Sutro Biopharma
$21.28 /

-1.6 (-6.99%)

SGMO Sangamo
$11.24 /

-0.61 (-5.15%)

PGEN Precigen
$6.79 /

-0.24 (-3.41%)

MRNA Moderna
$131.52 /

-2 (-1.50%)

BEAM Beam Therapeutics
$74.42 /

-2.26 (-2.95%)

Conference/Events
Wells Fargo to hold a virtual conference » 04:55
04/07/21
04/07
04:55
04/07/21
04:55
ADAP

Adaptimmune

$5.26 /

-0.35 (-6.24%)

, AGTC

Applied Genetic

$4.74 /

-0.26 (-5.20%)

, BLCM

Bellicum Pharmaceuticals

$3.63 /

-0.08 (-2.16%)

, BEAM

Beam Therapeutics

$76.80 /

-3.74 (-4.64%)

, AVRO

Avrobio

$11.71 /

-0.89 (-7.06%)

, CLLS

Cellectis

$19.80 /

-1.01 (-4.85%)

, CCXI

ChemoCentryx

$48.79 /

-0.65 (-1.31%)

, CALA

Calithera Biosciences

$2.48 /

-0.02 (-0.80%)

, HALO

Halozyme

$42.53 /

-0.33 (-0.77%)

, IMV

IMV Inc.

$3.19 /

-0.03 (-0.93%)

, MORF

Morphic

$60.97 /

-0.38 (-0.62%)

, MRNA

Moderna

$133.51 /

+3.74 (+2.88%)

, PGEN

Precigen

$7.03 /

-0.63 (-8.22%)

, QURE

uniQure

$35.92 /

+0.19 (+0.53%)

, TCON

Tracon Pharmaceuticals

$8.96 /

+0.3 (+3.46%)

, STRO

Sutro Biopharma

$22.88 /

-0.87 (-3.66%)

, SGMO

Sangamo

$11.85 /

-0.79 (-6.25%)

, RNA

Avidity Biosciences

$24.54 /

-0.44 (-1.76%)

, RGLS

Regulus

$1.48 /

-0.03 (-1.99%)

, ZIOP

Ziopharm

$3.42 /

-0.27 (-7.33%)

Biotech Corporate Access…

Biotech Corporate Access Day Virtual Conference will be held on April 6-8.

ShowHide Related Items >><<
ZIOP Ziopharm
$3.42 /

-0.27 (-7.33%)

TCON Tracon Pharmaceuticals
$8.96 /

+0.3 (+3.46%)

STRO Sutro Biopharma
$22.88 /

-0.87 (-3.66%)

SGMO Sangamo
$11.85 /

-0.79 (-6.25%)

RNA Avidity Biosciences
$24.54 /

-0.44 (-1.76%)

RGLS Regulus
$1.48 /

-0.03 (-1.99%)

QURE uniQure
$35.92 /

+0.19 (+0.53%)

PGEN Precigen
$7.03 /

-0.63 (-8.22%)

MRNA Moderna
$133.51 /

+3.74 (+2.88%)

MORF Morphic
$60.97 /

-0.38 (-0.62%)

IMV IMV Inc.
$3.19 /

-0.03 (-0.93%)

HALO Halozyme
$42.53 /

-0.33 (-0.77%)

CLLS Cellectis
$19.80 /

-1.01 (-4.85%)

CCXI ChemoCentryx
$48.79 /

-0.65 (-1.31%)

CALA Calithera Biosciences
$2.48 /

-0.02 (-0.80%)

BLCM Bellicum Pharmaceuticals
$3.63 /

-0.08 (-2.16%)

BEAM Beam Therapeutics
$76.80 /

-3.74 (-4.64%)

AVRO Avrobio
$11.71 /

-0.89 (-7.06%)

AGTC Applied Genetic
$4.74 /

-0.26 (-5.20%)

ADAP Adaptimmune
$5.26 /

-0.35 (-6.24%)

ADAP Adaptimmune
$5.26 /

-0.35 (-6.24%)

08/12/20 Piper Sandler
TCR2 Therapeutics initiated with an Overweight at Piper Sandler
06/01/20 Mizuho
Adaptimmune price target raised to $9 from $3 at Mizuho
05/29/20 JonesTrading
JonesTrading upgrades Adaptimmune to Buy after data alleviates 'key concern'
05/29/20 JonesTrading
Adaptimmune upgraded to Buy from Hold at JonesTrading
AGTC Applied Genetic
$4.74 /

-0.26 (-5.20%)

03/01/21 Stifel
Applied Genetic initiated with a Buy at Stifel
02/02/21 H.C. Wainwright
Applied Genetic price target raised to $24 from $18 at H.C. Wainwright
02/01/21 Roth Capital
Applied Genetic price target raised to $35 from $30 at Roth Capital
11/17/20 Roth Capital
Applied Genetic price target raised to $30 from $26 at Roth Capital
BLCM Bellicum Pharmaceuticals
$3.63 /

-0.08 (-2.16%)

10/30/20
Fly Intel: Top five analyst downgrades
10/30/20 Ladenburg
Bellicum Pharmaceuticals downgraded to Neutral from Buy at Ladenburg
10/30/20 Wells Fargo
Bellicum Pharmaceuticals downgraded to Equal Weight from Overweight at Wells Fargo
10/30/20 Wells Fargo
Bellicum downgraded to Equal Weight from Overweight at Wells Fargo
BEAM Beam Therapeutics
$76.80 /

-3.74 (-4.64%)

03/01/21 Barclays
Beam Therapeutics downgraded to Equal Weight from Overweight at Barclays
02/25/21 Wedbush
Beam Therapeutics price target raised to $112 from $42 at Wedbush
02/16/21
Fly Intel: Top five analyst initiations
02/16/21 Wells Fargo
Beam Therapeutics initiated with an Overweight at Wells Fargo
AVRO Avrobio
$11.71 /

-0.89 (-7.06%)

03/10/21 Stifel
Stifel says Bluebird update on AML provides 'some relief' to other LV players
03/09/21 Barclays
Avrobio initiated with an Overweight at Barclays
03/01/21 Stifel
Avrobio initiated with a Hold at Stifel
02/17/21 Mizuho
Avrobio selloff on Bluebird news a buying opportunity, says Mizuho
CLLS Cellectis
$19.80 /

-1.01 (-4.85%)

03/16/21 Baird
Cellectis upgraded to Outperform from Neutral at Baird
10/15/20 Baird
Cellectis downgraded to Neutral at Baird
10/15/20 Baird
Cellectis downgraded to Neutral from Outperform at Baird
08/19/20
Fly Intel: Top five analyst upgrades
CCXI ChemoCentryx
$48.79 /

-0.65 (-1.31%)

03/26/21 Piper Sandler
ChemoCentryx given FDA panel meeting on May 6, says Piper Sandler
03/02/21 H.C. Wainwright
ChemoCentryx price target raised to $101 from $83 at H.C. Wainwright
03/01/21 Stifel
ChemoCentryx initiated with a Buy at Stifel
12/22/20 Piper Sandler
Piper names ChemoCentryx a top pick for 2021, boosts target to $80
CALA Calithera Biosciences
$2.48 /

-0.02 (-0.80%)

01/05/21 SVB Leerink
Calithera Biosciences downgraded to Market Perform at SVB Leerink
01/05/21 SVB Leerink
Calithera Biosciences downgraded to Market Perform from Outperform at SVB Leerink
01/05/21 Citi
Calithera Biosciences price target lowered to $5 from $10 at Citi
01/05/21 H.C. Wainwright
Calithera Biosciences price target lowered to $4 from $9.50 at H.C. Wainwright
HALO Halozyme
$42.53 /

-0.33 (-0.77%)

01/25/21 BMO Capital
Halozyme price target raised to $65 from $56 at BMO Capital
01/21/21 Benchmark
Halozyme price target raised to $59 from $46 at Benchmark
01/14/21 Piper Sandler
Halozyme price target raised to $50 from $42 at Piper Sandler
01/11/21 Benchmark
Phesgo EU approval/Horizon deal fuel Halozyme increased guidance, says Benchmark
IMV IMV Inc.
$3.19 /

-0.03 (-0.93%)

12/29/20 Raymond James
Raymond James says IMV COVID plans look like 'red herring' to justify delay
07/21/20 Industrial Alliance
IMV Inc. initiated with a Buy at Industrial Alliance
07/14/20 Wells Fargo
IMV Inc. price target raised to $11 from $8.50 at Wells Fargo
05/18/20 Wells Fargo
IMV Inc. upgraded to Overweight on COVID-19 vaccine potential at Wells Fargo
MORF Morphic
$60.97 /

-0.38 (-0.62%)

03/03/21 SVB Leerink
Protagonist Therapeutics price target raised to $41 from $30 at SVB Leerink
03/01/21 Wells Fargo
Morphic Holding price target raised to $103 from $40 at Wells Fargo
02/02/21 RBC Capital
Morphic Holding price target raised to $50 from $35 at RBC Capital
10/26/20 RBC Capital
Morphic Holding initiated with an Outperform at RBC Capital
MRNA Moderna
$133.51 /

+3.74 (+2.88%)

03/15/21 Piper Sandler
Piper Sandler bullish on Moderna as first subject vaccinated in '1283 study
03/01/21 Chardan
Moderna price target raised to $182 from $107 at Chardan
02/26/21 Barclays
Moderna price target raised to $178 from $169 at Barclays
02/26/21 Brookline
Moderna price target raised to $205 from $180 at Brookline
PGEN Precigen
$7.03 /

-0.63 (-8.22%)

03/02/21 B. Riley
Precigen price target raised to $14 from $10 at B. Riley Securities
02/25/21 Stifel
Precigen initiated with a Buy at Stifel
02/22/21 Wells Fargo
Precigen initiated with an Overweight at Wells Fargo
02/18/21
Fly Intel: Top five analyst initiations
QURE uniQure
$35.92 /

+0.19 (+0.53%)

04/01/21
Fly Intel: Top five analyst upgrades
04/01/21 Mizuho
uniQure upgraded to Buy on favorable risk/reward at Mizuho
04/01/21 Mizuho
uniQure upgraded to Buy from Neutral at Mizuho
03/29/21 H.C. Wainwright
uniQure probe 'important first step' toward lifting hold, says H.C. Wainwright
TCON Tracon Pharmaceuticals
$8.96 /

+0.3 (+3.46%)

04/01/21 JonesTrading
Tracon Pharmaceuticals initiated with a Buy at JonesTrading
02/10/21
Fly Intel: Top five analyst initiations
02/10/21 Maxim
Tracon Pharmaceuticals initiated with a Buy at Maxim
12/04/20 H.C. Wainwright
Tracon Pharmaceuticals price target raised to $12 from $7 at H.C. Wainwright
STRO Sutro Biopharma
$22.88 /

-0.87 (-3.66%)

01/28/21 Truist
Sutro Biopharma price target raised to $37 from $24 at Truist
12/02/20 Stifel
Sutro Biopharma initiated with a Buy at Stifel
11/06/20 Piper Sandler
Sutro Biopharma price target raised to $22 from $20 at Piper Sandler
09/18/20 Piper Sandler
Piper Sandler lays out next potential takeover targets in oncology
SGMO Sangamo
$11.85 /

-0.79 (-6.25%)

03/03/21 Wells Fargo
Sangamo price target lowered to $29 from $36 at Wells Fargo
01/05/21 Stifel
Sangamo initiated with a Hold at Stifel
12/16/20 H.C. Wainwright
Sangamo assumed with a Buy at H.C. Wainwright
09/08/20 BofA
Sangamo resumed with a Buy at BofA
RNA Avidity Biosciences
$24.54 /

-0.44 (-1.76%)

07/07/20 Cowen
Avidity Biosciences initiated with an Outperform at Cowen
07/07/20 SVB Leerink
Avidity Biosciences initiated with an Outperform at SVB Leerink
07/07/20 Cowen
Avidity Biosciences initiated with an Outperform at Cowen
07/07/20 Wells Fargo
Avidity Biosciences initiated with an Overweight at Wells Fargo
RGLS Regulus
$1.48 /

-0.03 (-1.99%)

05/04/20 H.C. Wainwright
Regulus price target lowered to $1.50 from $2 at H.C. Wainwright
ZIOP Ziopharm
$3.42 /

-0.27 (-7.33%)

03/12/21 Jefferies
Ziopharm downgraded to Hold from Buy at Jefferies
03/01/21
Fly Intel: Top five analyst downgrades
03/01/21 H.C. Wainwright
Ziopharm downgraded to Neutral from Buy at H.C. Wainwright
07/10/20 Lake Street
Ziopharm took 'important step' with start of CAR-T study, says Lake Street
ZIOP Ziopharm
$3.42 /

-0.27 (-7.33%)

TCON Tracon Pharmaceuticals
$8.96 /

+0.3 (+3.46%)

STRO Sutro Biopharma
$22.88 /

-0.87 (-3.66%)

SGMO Sangamo
$11.85 /

-0.79 (-6.25%)

RNA Avidity Biosciences
$24.54 /

-0.44 (-1.76%)

RGLS Regulus
$1.48 /

-0.03 (-1.99%)

QURE uniQure
$35.92 /

+0.19 (+0.53%)

PGEN Precigen
$7.03 /

-0.63 (-8.22%)

MRNA Moderna
$133.51 /

+3.74 (+2.88%)

MORF Morphic
$60.97 /

-0.38 (-0.62%)

HALO Halozyme
$42.53 /

-0.33 (-0.77%)

CLLS Cellectis
$19.80 /

-1.01 (-4.85%)

CCXI ChemoCentryx
$48.79 /

-0.65 (-1.31%)

CALA Calithera Biosciences
$2.48 /

-0.02 (-0.80%)

BLCM Bellicum Pharmaceuticals
$3.63 /

-0.08 (-2.16%)

BEAM Beam Therapeutics
$76.80 /

-3.74 (-4.64%)

AVRO Avrobio
$11.71 /

-0.89 (-7.06%)

AGTC Applied Genetic
$4.74 /

-0.26 (-5.20%)

ADAP Adaptimmune
$5.26 /

-0.35 (-6.24%)

  • 03
    Mar
  • 28
    Jan
  • 22
    Jan
  • 16
    Dec
  • 09
    Dec
  • 20
    Nov
  • 01
    Oct
  • 11
    Jun
  • 12
    Jun
  • 02
    Jun
  • 19
    May
  • 12
    May
  • 16
    Apr
MRNA Moderna
$133.51 /

+3.74 (+2.88%)

ZIOP Ziopharm
$3.42 /

-0.27 (-7.33%)

STRO Sutro Biopharma
$22.88 /

-0.87 (-3.66%)

QURE uniQure
$35.92 /

+0.19 (+0.53%)

PGEN Precigen
$7.03 /

-0.63 (-8.22%)

MRNA Moderna
$133.51 /

+3.74 (+2.88%)

MORF Morphic
$60.97 /

-0.38 (-0.62%)

HALO Halozyme
$42.53 /

-0.33 (-0.77%)

CCXI ChemoCentryx
$48.79 /

-0.65 (-1.31%)

CALA Calithera Biosciences
$2.48 /

-0.02 (-0.80%)

BLCM Bellicum Pharmaceuticals
$3.63 /

-0.08 (-2.16%)

AVRO Avrobio
$11.71 /

-0.89 (-7.06%)

AGTC Applied Genetic
$4.74 /

-0.26 (-5.20%)

TCON Tracon Pharmaceuticals
$8.96 /

+0.3 (+3.46%)

STRO Sutro Biopharma
$22.88 /

-0.87 (-3.66%)

SGMO Sangamo
$11.85 /

-0.79 (-6.25%)

PGEN Precigen
$7.03 /

-0.63 (-8.22%)

MRNA Moderna
$133.51 /

+3.74 (+2.88%)

BEAM Beam Therapeutics
$76.80 /

-3.74 (-4.64%)

Conference/Events
Wells Fargo to hold a virtual conference » 09:16
04/06/21
04/06
09:16
04/06/21
09:16
ADAP

Adaptimmune

$5.61 /

+0.105 (+1.91%)

, AGTC

Applied Genetic

$5.00 /

-0.225 (-4.31%)

, BLCM

Bellicum Pharmaceuticals

$3.68 /

+0.01 (+0.27%)

, BEAM

Beam Therapeutics

$80.57 /

+0.87 (+1.09%)

, AVRO

Avrobio

$12.60 /

+0.295 (+2.40%)

, CLLS

Cellectis

$20.84 /

+1.08 (+5.47%)

, CCXI

ChemoCentryx

$49.51 /

-1.28 (-2.52%)

, CALA

Calithera Biosciences

$2.50 /

+ (+0.00%)

, HALO

Halozyme

$42.81 /

+0.47 (+1.11%)

, IMV

IMV Inc.

$3.22 /

+0.04 (+1.26%)

, MORF

Morphic

$61.14 /

-3.91 (-6.01%)

, MRNA

Moderna

$129.83 /

-2.68 (-2.02%)

, PGEN

Precigen

$7.66 /

+0.685 (+9.82%)

, QURE

uniQure

$35.73 /

+1.64 (+4.81%)

, TCON

Tracon Pharmaceuticals

$8.66 /

+0.11 (+1.29%)

, STRO

Sutro Biopharma

$23.75 /

+0.31 (+1.32%)

, SGMO

Sangamo

$12.64 /

+0.355 (+2.89%)

, RNA

Avidity Biosciences

$25.26 /

+2.87 (+12.82%)

, RGLS

Regulus

$1.50 /

-0.075 (-4.76%)

, ZIOP

Ziopharm

$3.68 /

+0.04 (+1.10%)

Biotech Corporate Access…

Biotech Corporate Access Day Virtual Conference will be held on April 6-8.

ShowHide Related Items >><<
ZIOP Ziopharm
$3.68 /

+0.04 (+1.10%)

TCON Tracon Pharmaceuticals
$8.66 /

+0.11 (+1.29%)

STRO Sutro Biopharma
$23.75 /

+0.31 (+1.32%)

SGMO Sangamo
$12.64 /

+0.355 (+2.89%)

RNA Avidity Biosciences
$25.26 /

+2.87 (+12.82%)

RGLS Regulus
$1.50 /

-0.075 (-4.76%)

QURE uniQure
$35.73 /

+1.64 (+4.81%)

PGEN Precigen
$7.66 /

+0.685 (+9.82%)

MRNA Moderna
$129.83 /

-2.68 (-2.02%)

MORF Morphic
$61.14 /

-3.91 (-6.01%)

IMV IMV Inc.
$3.22 /

+0.04 (+1.26%)

HALO Halozyme
$42.81 /

+0.47 (+1.11%)

CLLS Cellectis
$20.84 /

+1.08 (+5.47%)

CCXI ChemoCentryx
$49.51 /

-1.28 (-2.52%)

CALA Calithera Biosciences
$2.50 /

+ (+0.00%)

BLCM Bellicum Pharmaceuticals
$3.68 /

+0.01 (+0.27%)

BEAM Beam Therapeutics
$80.57 /

+0.87 (+1.09%)

AVRO Avrobio
$12.60 /

+0.295 (+2.40%)

AGTC Applied Genetic
$5.00 /

-0.225 (-4.31%)

ADAP Adaptimmune
$5.61 /

+0.105 (+1.91%)

ADAP Adaptimmune
$5.61 /

+0.105 (+1.91%)

08/12/20 Piper Sandler
TCR2 Therapeutics initiated with an Overweight at Piper Sandler
06/01/20 Mizuho
Adaptimmune price target raised to $9 from $3 at Mizuho
05/29/20 JonesTrading
JonesTrading upgrades Adaptimmune to Buy after data alleviates 'key concern'
05/29/20 JonesTrading
Adaptimmune upgraded to Buy from Hold at JonesTrading
AGTC Applied Genetic
$5.00 /

-0.225 (-4.31%)

03/01/21 Stifel
Applied Genetic initiated with a Buy at Stifel
02/02/21 H.C. Wainwright
Applied Genetic price target raised to $24 from $18 at H.C. Wainwright
02/01/21 Roth Capital
Applied Genetic price target raised to $35 from $30 at Roth Capital
11/17/20 Roth Capital
Applied Genetic price target raised to $30 from $26 at Roth Capital
BLCM Bellicum Pharmaceuticals
$3.68 /

+0.01 (+0.27%)

10/30/20
Fly Intel: Top five analyst downgrades
10/30/20 Ladenburg
Bellicum Pharmaceuticals downgraded to Neutral from Buy at Ladenburg
10/30/20 Wells Fargo
Bellicum Pharmaceuticals downgraded to Equal Weight from Overweight at Wells Fargo
10/30/20 Wells Fargo
Bellicum downgraded to Equal Weight from Overweight at Wells Fargo
BEAM Beam Therapeutics
$80.57 /

+0.87 (+1.09%)

03/01/21 Barclays
Beam Therapeutics downgraded to Equal Weight from Overweight at Barclays
02/25/21 Wedbush
Beam Therapeutics price target raised to $112 from $42 at Wedbush
02/16/21
Fly Intel: Top five analyst initiations
02/16/21 Wells Fargo
Beam Therapeutics initiated with an Overweight at Wells Fargo
AVRO Avrobio
$12.60 /

+0.295 (+2.40%)

03/10/21 Stifel
Stifel says Bluebird update on AML provides 'some relief' to other LV players
03/09/21 Barclays
Avrobio initiated with an Overweight at Barclays
03/01/21 Stifel
Avrobio initiated with a Hold at Stifel
02/17/21 Mizuho
Avrobio selloff on Bluebird news a buying opportunity, says Mizuho
CLLS Cellectis
$20.84 /

+1.08 (+5.47%)

03/16/21 Baird
Cellectis upgraded to Outperform from Neutral at Baird
10/15/20 Baird
Cellectis downgraded to Neutral at Baird
10/15/20 Baird
Cellectis downgraded to Neutral from Outperform at Baird
08/19/20
Fly Intel: Top five analyst upgrades
CCXI ChemoCentryx
$49.51 /

-1.28 (-2.52%)

03/26/21 Piper Sandler
ChemoCentryx given FDA panel meeting on May 6, says Piper Sandler
03/02/21 H.C. Wainwright
ChemoCentryx price target raised to $101 from $83 at H.C. Wainwright
03/01/21 Stifel
ChemoCentryx initiated with a Buy at Stifel
12/22/20 Piper Sandler
Piper names ChemoCentryx a top pick for 2021, boosts target to $80
CALA Calithera Biosciences
$2.50 /

+ (+0.00%)

01/05/21 SVB Leerink
Calithera Biosciences downgraded to Market Perform at SVB Leerink
01/05/21 SVB Leerink
Calithera Biosciences downgraded to Market Perform from Outperform at SVB Leerink
01/05/21 Citi
Calithera Biosciences price target lowered to $5 from $10 at Citi
01/05/21 H.C. Wainwright
Calithera Biosciences price target lowered to $4 from $9.50 at H.C. Wainwright
HALO Halozyme
$42.81 /

+0.47 (+1.11%)

01/25/21 BMO Capital
Halozyme price target raised to $65 from $56 at BMO Capital
01/21/21 Benchmark
Halozyme price target raised to $59 from $46 at Benchmark
01/14/21 Piper Sandler
Halozyme price target raised to $50 from $42 at Piper Sandler
01/11/21 Benchmark
Phesgo EU approval/Horizon deal fuel Halozyme increased guidance, says Benchmark
IMV IMV Inc.
$3.22 /

+0.04 (+1.26%)

12/29/20 Raymond James
Raymond James says IMV COVID plans look like 'red herring' to justify delay
07/21/20 Industrial Alliance
IMV Inc. initiated with a Buy at Industrial Alliance
07/14/20 Wells Fargo
IMV Inc. price target raised to $11 from $8.50 at Wells Fargo
05/18/20 Wells Fargo
IMV Inc. upgraded to Overweight on COVID-19 vaccine potential at Wells Fargo
MORF Morphic
$61.14 /

-3.91 (-6.01%)

03/03/21 SVB Leerink
Protagonist Therapeutics price target raised to $41 from $30 at SVB Leerink
03/01/21 Wells Fargo
Morphic Holding price target raised to $103 from $40 at Wells Fargo
02/02/21 RBC Capital
Morphic Holding price target raised to $50 from $35 at RBC Capital
10/26/20 RBC Capital
Morphic Holding initiated with an Outperform at RBC Capital
MRNA Moderna
$129.83 /

-2.68 (-2.02%)

03/15/21 Piper Sandler
Piper Sandler bullish on Moderna as first subject vaccinated in '1283 study
03/01/21 Chardan
Moderna price target raised to $182 from $107 at Chardan
02/26/21 Barclays
Moderna price target raised to $178 from $169 at Barclays
02/26/21 Brookline
Moderna price target raised to $205 from $180 at Brookline
PGEN Precigen
$7.66 /

+0.685 (+9.82%)

03/02/21 B. Riley
Precigen price target raised to $14 from $10 at B. Riley Securities
02/25/21 Stifel
Precigen initiated with a Buy at Stifel
02/22/21 Wells Fargo
Precigen initiated with an Overweight at Wells Fargo
02/18/21
Fly Intel: Top five analyst initiations
QURE uniQure
$35.73 /

+1.64 (+4.81%)

04/01/21
Fly Intel: Top five analyst upgrades
04/01/21 Mizuho
uniQure upgraded to Buy on favorable risk/reward at Mizuho
04/01/21 Mizuho
uniQure upgraded to Buy from Neutral at Mizuho
03/29/21 H.C. Wainwright
uniQure probe 'important first step' toward lifting hold, says H.C. Wainwright
TCON Tracon Pharmaceuticals
$8.66 /

+0.11 (+1.29%)

04/01/21 JonesTrading
Tracon Pharmaceuticals initiated with a Buy at JonesTrading
02/10/21
Fly Intel: Top five analyst initiations
02/10/21 Maxim
Tracon Pharmaceuticals initiated with a Buy at Maxim
12/04/20 H.C. Wainwright
Tracon Pharmaceuticals price target raised to $12 from $7 at H.C. Wainwright
STRO Sutro Biopharma
$23.75 /

+0.31 (+1.32%)

01/28/21 Truist
Sutro Biopharma price target raised to $37 from $24 at Truist
12/02/20 Stifel
Sutro Biopharma initiated with a Buy at Stifel
11/06/20 Piper Sandler
Sutro Biopharma price target raised to $22 from $20 at Piper Sandler
09/18/20 Piper Sandler
Piper Sandler lays out next potential takeover targets in oncology
SGMO Sangamo
$12.64 /

+0.355 (+2.89%)

03/03/21 Wells Fargo
Sangamo price target lowered to $29 from $36 at Wells Fargo
01/05/21 Stifel
Sangamo initiated with a Hold at Stifel
12/16/20 H.C. Wainwright
Sangamo assumed with a Buy at H.C. Wainwright
09/08/20 BofA
Sangamo resumed with a Buy at BofA
RNA Avidity Biosciences
$25.26 /

+2.87 (+12.82%)

07/07/20 Cowen
Avidity Biosciences initiated with an Outperform at Cowen
07/07/20 SVB Leerink
Avidity Biosciences initiated with an Outperform at SVB Leerink
07/07/20 Cowen
Avidity Biosciences initiated with an Outperform at Cowen
07/07/20 Wells Fargo
Avidity Biosciences initiated with an Overweight at Wells Fargo
RGLS Regulus
$1.50 /

-0.075 (-4.76%)

05/04/20 H.C. Wainwright
Regulus price target lowered to $1.50 from $2 at H.C. Wainwright
ZIOP Ziopharm
$3.68 /

+0.04 (+1.10%)

03/12/21 Jefferies
Ziopharm downgraded to Hold from Buy at Jefferies
03/01/21
Fly Intel: Top five analyst downgrades
03/01/21 H.C. Wainwright
Ziopharm downgraded to Neutral from Buy at H.C. Wainwright
07/10/20 Lake Street
Ziopharm took 'important step' with start of CAR-T study, says Lake Street
ZIOP Ziopharm
$3.68 /

+0.04 (+1.10%)

TCON Tracon Pharmaceuticals
$8.66 /

+0.11 (+1.29%)

STRO Sutro Biopharma
$23.75 /

+0.31 (+1.32%)

SGMO Sangamo
$12.64 /

+0.355 (+2.89%)

RNA Avidity Biosciences
$25.26 /

+2.87 (+12.82%)

RGLS Regulus
$1.50 /

-0.075 (-4.76%)

QURE uniQure
$35.73 /

+1.64 (+4.81%)

PGEN Precigen
$7.66 /

+0.685 (+9.82%)

MRNA Moderna
$129.83 /

-2.68 (-2.02%)

MORF Morphic
$61.14 /

-3.91 (-6.01%)

HALO Halozyme
$42.81 /

+0.47 (+1.11%)

CLLS Cellectis
$20.84 /

+1.08 (+5.47%)

CCXI ChemoCentryx
$49.51 /

-1.28 (-2.52%)

CALA Calithera Biosciences
$2.50 /

+ (+0.00%)

BLCM Bellicum Pharmaceuticals
$3.68 /

+0.01 (+0.27%)

BEAM Beam Therapeutics
$80.57 /

+0.87 (+1.09%)

AVRO Avrobio
$12.60 /

+0.295 (+2.40%)

AGTC Applied Genetic
$5.00 /

-0.225 (-4.31%)

ADAP Adaptimmune
$5.61 /

+0.105 (+1.91%)

  • 03
    Mar
  • 28
    Jan
  • 22
    Jan
  • 16
    Dec
  • 09
    Dec
  • 20
    Nov
  • 01
    Oct
  • 11
    Jun
  • 12
    Jun
  • 02
    Jun
  • 19
    May
  • 12
    May
  • 16
    Apr
MRNA Moderna
$129.83 /

-2.68 (-2.02%)

ZIOP Ziopharm
$3.68 /

+0.04 (+1.10%)

STRO Sutro Biopharma
$23.75 /

+0.31 (+1.32%)

QURE uniQure
$35.73 /

+1.64 (+4.81%)

PGEN Precigen
$7.66 /

+0.685 (+9.82%)

MRNA Moderna
$129.83 /

-2.68 (-2.02%)

MORF Morphic
$61.14 /

-3.91 (-6.01%)

HALO Halozyme
$42.81 /

+0.47 (+1.11%)

CCXI ChemoCentryx
$49.51 /

-1.28 (-2.52%)

CALA Calithera Biosciences
$2.50 /

+ (+0.00%)

BLCM Bellicum Pharmaceuticals
$3.68 /

+0.01 (+0.27%)

AVRO Avrobio
$12.60 /

+0.295 (+2.40%)

AGTC Applied Genetic
$5.00 /

-0.225 (-4.31%)

TCON Tracon Pharmaceuticals
$8.66 /

+0.11 (+1.29%)

STRO Sutro Biopharma
$23.75 /

+0.31 (+1.32%)

SGMO Sangamo
$12.64 /

+0.355 (+2.89%)

PGEN Precigen
$7.66 /

+0.685 (+9.82%)

MRNA Moderna
$129.83 /

-2.68 (-2.02%)

BEAM Beam Therapeutics
$80.57 /

+0.87 (+1.09%)

Recommendations
ChemoCentryx given FDA panel meeting on May 6, says Piper Sandler » 04:59
03/26/21
03/26
04:59
03/26/21
04:59
CCXI

ChemoCentryx

$51.05 /

-0.67 (-1.30%)

Piper Sandler analyst…

Piper Sandler analyst Edward Tenthoff reiterates an Overweight rating on ChemoCentryx with an $80 price target after the Federal Register indicated that the FDA's Arthritis Advisory Committee will host a meeting on May 6 to review the company's New Drug Application for avacopan for the treatment of ANCA-associated vasculitis ahead of the July 7 action date. The analyst is confident in avacopan approval based on the positive Phase III ADVOCATE data.

ShowHide Related Items >><<
CCXI ChemoCentryx
$51.05 /

-0.67 (-1.30%)

CCXI ChemoCentryx
$51.05 /

-0.67 (-1.30%)

03/02/21 H.C. Wainwright
ChemoCentryx price target raised to $101 from $83 at H.C. Wainwright
03/01/21 Stifel
ChemoCentryx initiated with a Buy at Stifel
12/22/20 Piper Sandler
Piper names ChemoCentryx a top pick for 2021, boosts target to $80
11/03/20 Piper Sandler
Piper confident in U.S. and EU approvals for ChemoCentryx's avacopan
CCXI ChemoCentryx
$51.05 /

-0.67 (-1.30%)

  • 11
    Jun
CCXI ChemoCentryx
$51.05 /

-0.67 (-1.30%)

Over a month ago
Hot Stocks
ChemoCentryx appoints Susan Kanaya to board of directors » 08:54
03/08/21
03/08
08:54
03/08/21
08:54
CCXI

ChemoCentryx

$57.19 /

-0.05 (-0.09%)

ChemoCentryx announced…

ChemoCentryx announced the appointment of Susan Kanaya, the Company's Executive Vice President and Chief Financial and Administrative Officer, to the ChemoCentryx Board of Directors effective March 2, 2021.

ShowHide Related Items >><<
CCXI ChemoCentryx
$57.19 /

-0.05 (-0.09%)

CCXI ChemoCentryx
$57.19 /

-0.05 (-0.09%)

03/02/21 H.C. Wainwright
ChemoCentryx price target raised to $101 from $83 at H.C. Wainwright
03/01/21 Stifel
ChemoCentryx initiated with a Buy at Stifel
12/22/20 Piper Sandler
Piper names ChemoCentryx a top pick for 2021, boosts target to $80
11/03/20 Piper Sandler
Piper confident in U.S. and EU approvals for ChemoCentryx's avacopan
CCXI ChemoCentryx
$57.19 /

-0.05 (-0.09%)

  • 11
    Jun
CCXI ChemoCentryx
$57.19 /

-0.05 (-0.09%)

Recommendations
ChemoCentryx price target raised to $101 from $83 at H.C. Wainwright » 06:15
03/02/21
03/02
06:15
03/02/21
06:15
CCXI

ChemoCentryx

$68.79 /

+0.89 (+1.31%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Edward White raised the firm's price target on ChemoCentryx to $101 from $83 and keeps a Buy rating on the shares following the company's Q4 results. The analyst sees potential Q3 approval for avacopan in AAV in the U.S. and Europe before the end of 2021.

ShowHide Related Items >><<
CCXI ChemoCentryx
$68.79 /

+0.89 (+1.31%)

CCXI ChemoCentryx
$68.79 /

+0.89 (+1.31%)

03/01/21 Stifel
ChemoCentryx initiated with a Buy at Stifel
12/22/20 Piper Sandler
Piper names ChemoCentryx a top pick for 2021, boosts target to $80
11/03/20 Piper Sandler
Piper confident in U.S. and EU approvals for ChemoCentryx's avacopan
10/29/20
Fly Intel: Top five analyst downgrades
CCXI ChemoCentryx
$68.79 /

+0.89 (+1.31%)

  • 11
    Jun
CCXI ChemoCentryx
$68.79 /

+0.89 (+1.31%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.